Institutional investors traded large blocks of shares in Sedemac Mechatronics, Brainbees Solutions, and Nephrocare on September 24. Meanwhile, HDFC Mutual Fund increased its holding in PB Fintech, despite the stock's recent price decline following regulatory updates from the IRDAI regarding insurance commission structures.
The Indian stock market witnessed a series of significant block deals on September 24, with institutional investors actively reshuffling their portfolios across various sectors. Sedemac Mechatronics was the focal point of the day's activity, recording a large transaction worth Rs 1,469 crore. This block deal involved 48.8 lakh shares, which were traded at a fixed price of Rs 3,010 per share. The sell-side saw private equity players, specifically A91 Emerging Fund II and funds associated with Xponentia Capital, reduce their stakes in the company. Conversely, the buyer list featured a strong lineup of institutional investors, including the Government of Singapore, the Monetary Authority of Singapore, along with prominent domestic mutual funds like SBI, ICICI Prudential, and Axis Mutual Fund. Global asset managers such as T Rowe Price and Franklin Templeton also participated in the buying activity.
In other market movements, Brainbees Solutions, the parent company of the e-commerce brand FirstCry, saw a trading volume of 1.83 crore shares, valued at Rs 321 crore. A significant part of this volume was driven by NewQuest Asia Investments, which sold 1.15 crore shares as part of a pre-IPO stake exit. Goldman Sachs acted as a buyer in this transaction, acquiring 68 lakh shares worth Rs 119 crore. Similarly, Nephrocare Health Services experienced a block deal involving 59 lakh shares, totaling Rs 415 crore. Edoras Investment Holdings, a long-term investor in the company, sold 25 lakh shares, while Polar Capital’s Healthcare Opportunities Fund stepped in as the major buyer, purchasing 25.46 lakh shares for Rs 179.5 crore. These exits by private equity firms are common in the financial lifecycle of companies as early investors look to realize returns.
In the financial sector, HDFC Mutual Fund increased its stake in PB Fintech through a purchase of 25 lakh shares at Rs 1,282.30 per share, totaling an investment of Rs 320.6 crore. This move is particularly notable as it comes after PB Fintech shares saw a 36% correction recently. The stock price drop was linked to concerns regarding IRDAI regulatory updates on insurance commission structures, which could impact the profitability models of insurance distributors. Investors often watch such moves by large mutual funds as a signal of long-term confidence despite short-term regulatory uncertainty. Finally, Aventis Pharma witnessed an internal promoter reorganization. Hoechst GmbH transferred 35 lakh shares to Sanofi Healthcare India in a deal valued at Rs 1,068 crore. This was an intra-group arrangement rather than a market-driven sell-off or shift in ultimate ownership.